Research Article

Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer

Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China

‡Authors contributed equally

Search for more papers by this author

Gengpu Zhang‡

‡Authors contributed equally

Search for more papers by this author

Xin Li‡

‡Authors contributed equally

Search for more papers by this author

Xiaojie Li

Search for more papers by this author

XiaoBing Chen

Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China

Search for more papers by this author

Yu Xu

Department of Oncology, Tianjin Huanghe Hospital, Tianjin, 300060, China

Search for more papers by this author

He Ren

*Author for correspondence:

E-mail Address: renhe@tjmuch.com

Department of Gastroenterology, Center of Tumor Immunology & Cytotherapy, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China

Search for more papers by this author

Published Online:14 Jun 2021https://doi.org/10.2217/pgs-2020-0183

View article

Abstract

Aim: The prognosis of resectable pancreatic cancer patients with the same stage of disease is highly variable. The purpose of this study is to establish a scoring system for preoperative screening of resectable patients. Materials & methods: The clinical information and laboratory tests of 105 resectable patients with pancreatic cancer were enrolled and analyzed. Results: The consistency of clinical stage and pathological stage was poor (κ = 0.193; p < 0.003). We performed a comprehensive scoring system with KRAS mutations in circulating tumor DNA (^mutKRAS ctDNA) for the resectable patients. Patients with higher scores were more prone to early postoperative recurrence and poorer prognosis. Conclusion: The scoring system can help preoperatively screen out resectable patients who are prone to early postoperative recurrence.

Keywords:

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
MedlineGoogle Scholar
2. Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary management of localized resectable pancreatic cancer. Cancers (Basel) 10(1), 24 (2018).
MedlineGoogle Scholar
3. Groot VP, Gemenetzis G, Blair AB et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann. Surg. 269(6), 1154–1162 (2019).
MedlineGoogle Scholar
4. Hadano N, Murakami Y, Uemura K et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br. J. Cancer 115(1), 59–65 (2016).
Medline CASGoogle Scholar
5. Ni XG, Bai XF, Mao YL et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur. J. Surg. Oncol. 31(2), 164–169 (2005).
Medline CASGoogle Scholar
6. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. Clin. Chim. Acta 411(21–22), 1611–1624 (2010).
Medline CASGoogle Scholar
7. Chu D, Paoletti C, Gersch C et al. ESR1 mutations in circulating plasma tumor dna from metastatic breast cancer patients. Clin. Cancer Res. 22(4), 993–999 (2016).
Medline CASGoogle Scholar
8. El Messaoudi S, Mouliere F, Du Manoir S et al. Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal cancer patient management care. Clin. Cancer Res. 22(12), 3067–3077 (2016).
MedlineGoogle Scholar
9. Camps C, Jantus-Lewintre E, Cabrera A et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer 72(3), 365–369 (2011).
MedlineGoogle Scholar
10. Iqbal S, Vishnubhatla S, Raina V et al. Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. Springerplus 4, 265 (2015).
MedlineGoogle Scholar
11. Bournet B, Buscail C, Muscari F, Cordelier P, Buscail L. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: hopes and realities. Eur. J. Cancer 54, 75–83 (2016).
Medline CASGoogle Scholar
12. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757–1765 (2008).
Medline CASGoogle Scholar
13. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883–892 (2012).
Medline CASGoogle Scholar
14. Zhang J, Fujimoto J, Zhang J et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346(6206), 256–259 (2014).
Medline CASGoogle Scholar
15. Yang M, Forbes ME, Bitting RL et al. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann. Oncol. 29(2), 311–323 (2018).
Medline CASGoogle Scholar
16. Frenel JS, Carreira S, Goodall J et al. Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin. Cancer Res. 21(20), 4586–4596 (2015).
Medline CASGoogle Scholar
17. Mirkin KA, Greenleaf EK, Hollenbeak CS, Wong J. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. Int. J. Surg. 52, 221–228 (2018).
MedlineGoogle Scholar
18. Chang JC, Kundranda M. Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int. J. Mol. Sci. 18(3), 667 (2017).
Google Scholar
19. Duffy MJ, Sturgeon C, Lamerz R et al. Tumor markers in pancreatic cancer: a European Group on tumor markers (EGTM) status report. Ann. Oncol. 21(3), 441–447 (2010).
Medline CASGoogle Scholar
20. Capello M, Bantis LE, Scelo G et al. Sequential validation of blood-based protein biomarker candidates for early-stage pancreatic cancer. J. Natl Cancer Inst. 109(4), (2017).
MedlineGoogle Scholar
21. Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J. Gastroenterol. 20(31), 10802–10812 (2014).
MedlineGoogle Scholar
22. Luo G, Liu C, Guo M et al. Potential biomarkers in lewis negative patients with pancreatic cancer. Ann. Surg. 265(4), 800–805 (2017).
MedlineGoogle Scholar
23. Hong SM, Park JY, Hruban RH, Goggins M. Molecular signatures of pancreatic cancer. Arch. Pathol. Lab. Med. 135(6), 716–727 (2011).
Medline CASGoogle Scholar
24. Waddell N, Pajic M, Patch AM et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540), 495–501 (2015).
Medline CASGoogle Scholar
25. Di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 144(6), 1220–1229 (2013).
MedlineGoogle Scholar
26. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72(10), 2457–2467 (2012).
Medline CASGoogle Scholar
27. Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J. Biomed. Biotechnol. 2010, 150960 (2010).
MedlineGoogle Scholar
28. Kruger S, Heinemann V, Ross C et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann. Oncol. 29(12), 2348–2355 (2018).
Medline CASGoogle Scholar
29. Bernard V, Kim DU, San Lucas FA et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology 156(1), 108–118 e104 (2019).
Medline CASGoogle Scholar
30. Pietrasz D, Pecuchet N, Garlan F et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin. Cancer Res. 23(1), 116–123 (2017).
Medline CASGoogle Scholar
31. Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: a surveillance, epidemiology and end results (SEER) analysis. Ann. Surg. Oncol. 24(7), 2023–2030 (2017).
MedlineGoogle Scholar
32. Maire F, Micard S, Hammel P et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br. J. Cancer 87(5), 551–554 (2002).
Medline CASGoogle Scholar
33. Alcaide M, Cheung M, Bushell K et al. A novel multiplex droplet digital PCR assay to identify and quantify KRAS mutations in clinical specimens. J. Mol. Diagn. 21(2), 214–227 (2018).
MedlineGoogle Scholar

Vol. 22, No. 11

Supplemental Materials

Metrics

Downloaded 170 times

History

Received 15 November 2020

Accepted 12 May 2021

Published online 14 June 2021

Published in print July 2021

Information

Keywords

Author contributions

S Li and X Li contributed to the research experiments. Y Xu participated in the data acquisition. S Li, G Zhang and X Li contributed to the data analysis and interpretation. G Zhang and X Li contributed to the statistical analysis. S Li contributed to the drafting of manuscript. XB Chen participated in the revision of this manuscript and the formulation of technical standards. H Ren contributed to the manuscript revision and the study supervision.

Financial & competing interests disclosure

Supported by the Taishan Scholars Program of Shandong Province, the National Natural Science Foundation of China (grants 81525021, 81672431, 81672435, 81720108028, 81772633, 81702426, 81702427, 81572618, 81802432, 81802433, 81871968 and 81871978). Key Program of Prevention and Treatment of Chronic Diseases of Tianjin (17ZXMFSY001), the programs of Tianjin Prominent Talents, Tianjin Eminent Scholars and Tianjin Natural Science Fund for Distinguished Young Scholar. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that this study was approved by the Ethics Committee of Tianjin Cancer Institute and Hospital and have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, all participants involved signed the informed consent.

PDF download